NeoGenomics Inc

Financials

Flusso di cassa derivante dalle attività operative 1.46 M-26.72 M-65.99 M-1.95 M7.02 M5.23 M 5.23 M Flussi di cassa derivanti dalle attività di investimento -159.44 M-632.37 M517 K76.71 M12.86 M-12.34 M -12.34 M Liquidità derivante dalle attività di finanziamento 235.6 M725.28 M11.83 M4.55 M4.65 M-200.29 M -200.29 M Liquidità libera -27.64 M-90.86 M-96.88 M-30.7 M-34.04 M-21.78 M -21.78 M

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.

NEO

Financials

NeoGenomics Inc

Notizie

Neo Performance Q4 2025: crescita EBITDA ma EPS delude

Neo Performance Q4 2025 non raggiunge le previsioni sull’EPS

William Blair conferma Market Perform su Neogenomics dopo decisione copertura Medicare

William Blair reiterates Market Perform on Neogenomics stock after Medicare coverage decision

Neogenomics ottiene copertura Medicare per test ematico

Neogenomics stock gets Medicare coverage for blood-based test

Neogenomics ottiene rimborso MolDX per test oncologico

Neogenomics stock gets MolDX reimbursement for cancer test

Il test PanTracer LBx di NeoGenomics ottiene copertura Medicare

NeoGenomics’ PanTracer LBx test receives Medicare coverage

NeoGenomics alla Conferenza Leerink: Focus sulla Crescita Strategica

NeoGenomics at Leerink Conference: Strategic Growth Focus